Neoleukin Therapeutics (NLTX) Peer Comparison

$3.49

$-10.47 (-75.00%)

As on 19-Dec-2023 09:30EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Market cap ($ Mln)	8	93	16	43,155
Revenue ($ Mln)	--	1	0	2,300
Net Profit ($ Mln)	-39.36	-27.12	-60.92	-750.23
Net Margin (%)	281,135.71	-2,430.11	1,778.97	-32.61
RoE (%)	-54.63	-125.15	--	-28.45
Price to Earnings	--	--	--	--
Price-To-Book	0.44	5.98	17.26	16.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Operating Revenue	0.00	0.95	0.00	1,962.41
Cost of Revenue	--	0.50	--	410.06
Gross Profit	0.01	0.45	1.26	1,552.35
Operating Expenses	59.10	30.70	24.61	2,165.32
Operating Profit (EBIT)	-59.10	-30.25	-24.61	-612.97
Other Income	0.01	--	--	--
Profit before Tax	-57.56	-29.96	-26.24	-602.32
Provision for Tax	-1.54	0.05	1.62	7.99
Profit after Tax (Net Income)	-56.02	-30.01	-27.86	-610.31
Minority Interest	--	--	--	--
Consolidated Profit	-57.56	-14.67	-15.37	-610.31

Liabilities ($ Mln)

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Shareholder's Funds	94.33	26.11	-16.76	2,803.82
Minority Interest	--	--	--	--
Non-Current Liabilities	10.56	3.71	9.43	52.31
Current Liabilities	11.06	4.95	18.95	818.40
Total Liabilities	115.95	34.76	11.62	3,674.53

Assets ($ Mln)

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Non-Current Assets	16.81	7.45	8.11	1,939.46
Current Assets	99.13	27.31	3.52	1,735.07
Total Assets	115.95	34.76	11.62	3,674.53
Total Debt*	12.07	3.55	11.86	43.47
Net Current Assets	88.07	22.36	-15.44	1,984.13

Cashflow ($ Mln)

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Cash From Operating Activities	-45.61	-26.68	-30.25	-453.75
Cash Flow from Investing Activities	-59.13	-1.38	-0.05	228.24
Cash from Financing Activities	0.16	0.17	20.04	125.36
Net Cash Inflow / Outflow	-50.09	--	--	-100.15

Ratios

Profitability Ratios

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
ROCE (%)	-42.72	-70.93	894.87	-20.45
ROE (%)	-47.23	-74.80	301.44	-20.80
ROA (%)	-40.13	-62.72	-116.37	-16.51
EBIT Margin (%)	--	--	--	--
Net Margin (%)	-486,791.67	-3,147.22	-1,168.94	-31.10
Cash Profit Margin (%)	--	--	--	--

Growth Ratios

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Revenue Growth (%)	-1.00	27.84	-1.00	0.25
EBIT Growth (%)	--	--	--	--
Net Profit Growth (%)	4.11	-100.64	-89.16	9.51
EPS Growth (%)	0.04	-0.05	-0.66	0.11
Book Value Growth (%)	--	--	--	--

Valuation Ratios

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Price / Earnings	-0.50	-2.09	-1.44	-39.18
Price / Book Value	0.30	2.41	-2.40	8.53
Dividend Yield (%)	--	--	--	--
EV/EBITDA	0.99	-1.38	-2.00	-35.64
Market Cap ($ Cr)	--	--	--	--

Solvency Ratios

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Debt to Equity	0.13	0.14	-0.71	0.02
Short term debt to equity ratio	0.02	0.02	-0.15	--
Current Ratio	8.96	5.52	0.19	2.12
Quick Ratio	--	5.36	0.93	1.60
Interest Coverage	-37.36	-633.66	-242.67	-5.92

Operating Efficiency Ratios

	Neoleukin Therapeutics (NLTX)	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Seagen (SGEN)
Debtors to sales (%)	--	108.89	396.83	25.58
Asset Turnover	0.00	0.02	0.00	0.53
Receivable days	54,787.50	443.02	1,449.40	82.93
Inventory Days	--	584.47	--	279.63
Payable days	--	1,344.04	--	143.71
Cash Conversion Cycle	--	-316.54	--	218.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly